• Explore /
  • Poster
  • / Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.

Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.

Abstract Poster

Authors

null

Jenny Furlanetto

Medical Oncology, University of Verona, Verona, Italy

Jenny Furlanetto , Vanja Vaccaro , Chiara Caliolo , Michele De Laurentiis , Maria Bonomi , Sara Pilotto , Francesco Massari , Rolando Nortilli , Daniela Cianniello , Francesco Cognetti , Diana Giannarelli , Giampaolo Tortora , Emilio Bria

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Citation

J Clin Oncol 30, 2012 (suppl; abstr 630)

DOI

10.1200/jco.2012.30.15_suppl.630

Abstract #

630

Poster Bd #

13A

Abstract Disclosures

Similar Posters

First Author: Emanuela Risi

First Author: Takashi Ishikawa

First Author: G. Von Minckwitz

First Author: Tarek Mohamed Ahmed Abdel-Fatah